Study characteristics of the 11 randomised controlled trials enrolled
| Trials year | Location | Interventions (number of patients) | Age (mean±SD) | Baseline VA (ETDRS, letters) | Follow-up (months) |
| GENEVA44–46 | International | DEX 0.7 mg (n=136) | Mean 62.7 to 65.2 years | 52.4±10.6 | 6, 12 |
| 2010 | DEX 0.35 mg (n=154) | NA | |||
| Sham (n=147) | 53.3±10.8 | ||||
| ROVO47 | Austria | Tria 4 mg (n=25) | NA | 46.5 | 12 |
| 2015 | RON (n=38) | (overall) | |||
| Pla (n=20) | |||||
| SCORE48–54 | United States | Tria 4 mg (n=91) | 67.5±12.0 | 51.0±14.4 | Every 4 months for 36 months |
| 2013 | Tria 1 mg (n=92) | 67.4±12.4 | 50.6±14.9 | ||
| Obs (n=88) | 69.2±12.8 | 52.1±13.1 | |||
| CRUISE20 65–67 | United State | IVR 0.3 mg (n=132) | 69.7±11.6 | 47.4±14.8 | Monthly visits up to 12 months |
| 2010 | IVR 0.5 mg (n=130) | 67.6±12.4 | 48.1±14.6 | ||
| Sham (n=130) | 65.4±13.1 | 49.2±14.7 | |||
| ROCC67 | Norway | IVR 0.5 mg (n=15) | 72 | 45±23 | 6 |
| 2010 | Sham (n=14) | 41±22 | |||
| COPERNICUS68 69 | International | IAI 2 mg (n=114) | 65.5±13.5 | 50.7±13.9 | 6 |
| 2012 | Sham (n=73) | 67.5±14.3 | 48.9±14.4 | ||
| GALILEO70 71 | International | IAI 2 mg (n=103) | 59.9±12.4 | 53.6±15.8 | 6,12 |
| 2013 | Sham (n=71) | 63.8±13.3 | 50.9±15.4 | ||
| Epstein72–74 | Sweden | IVB 0.25 mg (n=30) | 70.6±12.6 | 70.6±12.6 | 6,12 |
| 2012 | Sham (n=30) | 70.4±10.4 | 70.4±10.4 | ||
| Wroblewski23 75–80 | International | IVP 0.3 mg (n=33) | 64 | 47.6 | 12 |
| 2009 | IVP 1 mg (n=33) | 64 | 48.4 | ||
| Sham (n=32) | 59 | 48.5 | |||
| Ramezani81 | Iran | IVB 1.25 mg (n=43) | 60±8 | 0.87±0.49logMAR | 6 |
| 2014 | Tria 2 mg (n=43) | 59±9 | 0.81±0.45logMAR | ||
| COMRADE-C83 | International | IVR 0.5 mg (n=124) | 65.3±11.4 | 61.7±16.5 | 1, 6 |
| 2016 | DEX (n=119) | 66.9±12.4 | 51.5±15.6 |
DEX, dexamethasone; IAI, intravitreal aflibercept injections; IVB, intravitreal bevacizumab injections; IVP, intravitreal pegaptanib injections; IVR, intravitreal ranibizumab injections; Obs, observation; Pla, placebo; RON, radial optical neurotomy; Tria, triamcinolone; VA, visual acuity. ETDRS, Early Treatment of Diabetic Retinopathy Study; ROVO, Radial Optic Neurotomy for Central Vein Occlusion; SCORE, Standard Care vs. Corticosteroid for Retinal Vein Occlusion; COMRADE-C, Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion.